Our Technology Partn3Ring webinars showcase technologies with 3Rs potential to the wider scientific community to identify new partners for further development, qualification and use. Webinars consist of short pitches outlining the 3Rs technologies and unique opportunities for collaboration.
The next Technology Partn3Ring webinar topic will be delivered as a fortnightly webinar series between April and July 2026, reflecting the interest from researchers and technology developers working in new approach methodologies (NAMs), which are replacement technologies for use in assessing chemical or drug toxicity.
The series is open to researchers, clinicians, pharmaceutical and industry professionals. Audience members will be able to ask questions to the speakers and connect with the speakers to access unique collaboration opportunities.
Recordings of sessions will be available to re-watch on this page shortly after the session.
Scheduled dates, open for registration:
- Wednesday 22 April, 14.00 – 15.15 (BST)
- Wednesday 6 May, 14.00 – 15.15 (BST)
Future dates, subject to speaker availability:
- Wednesday 20 May, 14.00 (BST)
- Wednesday 3 June, 14.00 (BST)
- Wednesday 17 June, 14.00 (BST)
- Wednesday 1 July, 14.00 (BST)
- Wednesday 15 July, 14.00 (BST)
- Wednesday 29 July, 14.00 (BST)
Subscribe to our NC3Rs newsletter and follow us on LinkedIn and Bluesky for the latest updates on this series. Researchers in this area can also engage with our NAMs Network that supports scientists from across sectors to establish collaborations and catalyses the uptake of 3Rs technologies.
Upcoming webinars
Register for session 1: Wednesday 22 April, 14.00 – 15.15 (BST)
The first NAMs webinar will include presentations from researchers working across invertebrate models as partial replacements for the use of mammals, human-relevant microphysiological models, drug efficacy and drug/consumer product toxicity testing.
Early drug screening with C. elegans: A 3Rs-aligned approach
Sara Leighton (Magnitude Biosciences Limited)
• High-throughput C. elegans platform, delivering scalable and predictive insights on drug efficacy, safety and mechanism of action.
• Seeking collaborators to further qualify screening platform and provide access to comparator datasets.
From model to method: Validating C. elegans-based DART assay towards regulatory use
Eva Martini (Nagi Bioscience)
• Providing human relevant whole organism toxicity data that can replace early mammalian screens.
• Seeking collaborators for new toxicology use cases, cross‑species comparison, and standardisation towards regulatory readiness.
Title TBC
Margaret Magdesian (Ananda Devices)
• Developing human iPSC‑based neuro and neuromuscular assays towards replacing animal use in neurotoxicity assays.
• Seeking partners to benchmark and expand applications, including exploring incorporation into regulatory workflows.
Title TBC
Vitaliy Khutoryanskiy (University of Reading)
• Developing invertebrate assays that can replace early-stage mammalian studies in toxicity, irritation, infection and formulation screening.
• Seeking collaborators interested in co-developing and qualifying the invertebrate-based assays for broader application and increased translational relevance.
Register for session 2: Wednesday 6 May, 14.00 – 15.15 (BST)
The second NAMs session will include presentations from researchers working across human relevant in vitro technologies, ranging from brain tumour modelling, stem cell platforms in toxicity and imaging, cell-based assays in safety assessment and organ function studies.
Amrita Singh (Integral Molecular)
• Human-relevant membrane proteome array to assess off-target binding of antibody-based therapies early in development.
• Seeking new users of technology to focus on expanding 3Rs benefits.
Davide Danovi (Migration Biotherapeutics)
• Human iPSC-based neural spheroid platform modelling tumour-brain interactions in glioblastoma.
• Looking for collaborators to further develop the model and quantify cancer cell migration.
Ciara Doran (Sansanima Limited)
• Non-animal, cell‑based assays for safety and potency testing of Clostridials.
• Seeking partners for quality, process control or next generation development of botulinum toxin.
James L. Sherley (Asymmetrex® LLC)
• Rapid, accurate counting and monitoring of tissue stem cells in heterogeneous tissue cell preparations in in vitro drug toxicity assessment.
• Seeking collaborators to help assess predictive value of technology in drug candidates known to cause chronic organ failure.
Jiwu Wang (Allele Biotechnology)
• Bioprinted iPSC derived liver mini-organs to replace in vivo organ function studies in drug development.
• Seeking teams with liver specific assay expertise to further qualify the model in longitudinal studies.